StageZero Life Sciences Ltd T.SZLS

Alternate Symbol(s): SZLSF

Healthcare Biotechnology

StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is engaged in improving the early detection and management of cancer and other chronic diseases through diagnostics and telehealth programs that provide clinical interventions to assist patients who have cancer (COC Protocol), and help patients reduce the risk of developing late-stage disease (AVRT). Its test, Aristotle, is the first mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. Aristotle uses mRNA technology to identify the molecular signatures of multiple cancer types and is built on the Company's patented technology platform, the Sentinel Principle. The Care Oncology Clinic offers a supervised treatment regimen (the COC Protocol) for people diagnosed with cancer of any type or stage. Its ColonSentry is a proprietary blood test for screening for Colorectal Cancer.

TSX:SZLS - Post by User

StageZero Life Sciences Ltd > No Volume

<< Previous

Bullboard Posts

Next >>

Comment by IainCaimbeulon Mar 26, 2021 4:07pm

124 Views

Post# 32888250

RE:RE:RE:RE:No Volume

That's business as usual for both the stock and the warrants for StageZero.
Until there is a proper rollout for Aristotle expect more of the same.
You could not give this stock/warrants away today.
So, go to Happy Hour, have a large double rum and your hangover should subide on or about 31 Mar 2021. :)

<< Previous

Bullboard Posts

Next >>

POET increases production capacity to meet AI demand